The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
Open accessAbstract
We recently found that microRNA-34a (miR-34a) is downregulated in human glioma tumors as compared to normal brain, and that miR-34a levels in mutant-p53 gliomas were lower than in wildtype-p53 tumors. We showed that miR-34a expression in glioma and medulloblastoma cells inhibits cell proliferation, G1/S cell cycle progression, cell survival, cell migration and cell invasion, but that miR-34a expression in human astrocytes does not affect cell survival and cell cycle. We uncovered the oncogenes c-Met, Notch-1 and Notch-2 as direct targets of miR-34a that are inhibited by miR-34a transfection. We found that c-Met levels in human glioma specimens inversely correlate with miR-34a levels. We showed that c-Met and Notch partially mediate the inhibitory effects of miR-34a on cell proliferation and cell death. We also found that mir-34a expression inhibits in vivo glioma xenograft growth. We concluded that miR-34a is a potential tumor suppressor in brain tumors that acts by targeting multiple oncogenes. In this extra view, we briefly review and discuss the implications of these findings and present new data on the effects of miR-34a in glioma stem cells. The new data show that miR-34a expression inhibits various malignancy endpoints in glioma stem cells. Importantly, they also show for the first time that miR-34a expression induces glioma stem cell differentiation. Altogether, the data suggest that miR-34a is a tumor suppressor and a potential potent therapeutic agent that acts by targeting multiple oncogenic pathways in brain tumors and by inducing the differentiation of cancer stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311
Self-citationTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
miR-34a repression of SIRT1 regulates apoptosis
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801613105 · Cited by 1,342
Repression of protein synthesis by miRNAs: how many mechanisms?
Pillai, R. S., Bhattacharyya, S. N., & Filipowicz, W. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.12.007 · Cited by 1,108
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4436 · Cited by 923
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
Welch, C., Chen, Y., & Stallings, R. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210293 · Cited by 805
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., Lee, J., Fine, H., Chiocca, E. A., Lawler, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6639 · Cited by 647
Self-citationMicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614
Self-citationPurow, B. W., Haque, R. M., Noel, M. W., Su, Q., Burdick, M. J., Lee, J., Sundaresan, T., Pastorino, S., Park, J. K., Mikolaenko, I., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1890 · Cited by 583
Self-citationDownregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest
Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., Sun, Z., & Zheng, X. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.03.057 · Cited by 514
Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., & Zheng, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.09.035 · Cited by 418
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp219 · Cited by 342
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Abounader, R., & Laterra, J. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000050 · Cited by 300
Self-citationThe MYCN oncogene is a direct target of miR-34a
Wei, J. S., Song, Y. K., Durinck, S., Chen, Q.-R., Cheuk, A. T. C., Tsang, P., Zhang, Q., Thiele, C. J., Slack, A., Shohet, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.154 · Cited by 296
Sizing up miRNAs as cancer genes
Caldas, C., & Brenton, J. D. (2005) · Nature Medicine · doi:10.1038/nm0705-712 · Cited by 202
Identification of microRNAs and Other Tiny Noncoding RNAs by cDNA Cloning
Ambros, V., & Lee, R. C. (2004) · RNA Interference, Editing, and Modification · doi:10.1385/1-59259-775-0:131 · Cited by 184
Barbashina, V., Salazar, P., Holland, E. C., Rosenblum, M. K., & Ladanyi, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1119.11.3 · Cited by 182
Abounader, R., Ranganathan, S., Lal, B., Fielding, K., Book, A., Dietz, H., Burger, P., & Laterra, J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1548 · Cited by 177
Self-citationNotch-1 regulates transcription of the epidermal growth factor receptor through p53
Purow, B. W., Sundaresan, T. K., Burdick, M. J., Kefas, B. A., Comeau, L., Hawkinson, M. P., Su, Q., Kotliarov, Y., Lee, J., Zhang, W., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn079 · Cited by 132
Self-citationLi, Y.-Q., Lal, B., Kwon, S., Fan, X., Saldanha, U., Reznik, T. E., Kuchner, E. B., Eberhart, C. G., Laterra, J., & Abounader, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1946 · Cited by 117
Self-citationPTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95
Self-citationSignaling pathways in medulloblastoma
Guessous, F., Li, Y., & Abounader, R. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21542 · Cited by 83
Self-citationMoriyama, T., Kataoka, H., Kawano, H., Yokogami, K., Nakano, S., Goya, T., Uchino, H., Koono, M., & Wakisaka, S. (1998) · Cancer Letters · doi:10.1016/s0304-3835(97)00469-2 · Cited by 74
Li, Y.-Q., Guessous, F., Johnson, E., Eberhart, C. G., Li, X.-N., Shu, Q., Fan, S., Lal, B., Laterra, J., Schiff, D., et al. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700702 · Cited by 70
Self-citation17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
Dijkstra, M. K., van Lom, K., Tielemans, D., Elstrodt, F., Langerak, A. W., Veer, M. B. V., & Jongen‐Lavrencic, M. (2008) · Leukemia · doi:10.1038/leu.2008.264 · Cited by 63
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Li, Y., Guessous, F., diPierro, C. G., Zhang, Y., Mudrick, T., Fuller, L., Johnson, E. K., Marcinkiewicz, L., Engelhardt, M., Kefas, B. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0627 · Cited by 44
Self-citation
Cited by
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313
Cancer stem cells: problems for therapy?
Alison, M. R., Lim, S. M., & Nicholson, L. J. (2011) · The Journal of Pathology · doi:10.1002/path.2793 · Cited by 312
MicroRNA-34a: a potential therapeutic target in human cancer
Li, X. J., Ren, Z. J., & Tang, J. H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.270 · Cited by 287
Metadata
- Authors
- Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., & Abounader, R.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2010-03-15
- Volume
- 9
- Issue
- 6
- Pages
- 1031-1036
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2147730829
- Cited by
- 306
- References
- 32
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.